While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. That said, here is one profitable company that balances growth and profitability and two that may struggle to keep up.
Two Stocks to Sell:
Pool (POOL)
Trailing 12-Month GAAP Operating Margin: 10.8%
Founded in 1993 and headquartered in Louisiana, Pool (NASDAQ: POOL) is one of the largest wholesale distributors of swimming pool supplies, equipment, and related leisure products.
Why Do We Think POOL Will Underperform?
- Sales trends were unexciting over the last five years as its 2.2% annual growth was below the typical consumer discretionary company
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
At $205.34 per share, Pool trades at 17.7x forward P/E. Read our free research report to see why you should think twice about including POOL in your portfolio.
CVS Health (CVS)
Trailing 12-Month GAAP Operating Margin: 2%
With over 9,000 retail pharmacy locations serving as neighborhood health destinations across America, CVS Health (NYSE: CVS) operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna subsidiary.
Why Is CVS Not Exciting?
- Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 6.9% for the last two years
- Estimated sales growth of 1.7% for the next 12 months implies demand will slow from its two-year trend
- Annual earnings per share growth of 1.1% underperformed its revenue over the last five years, showing its incremental sales were less profitable
CVS Health’s stock price of $95.56 implies a valuation ratio of 11.9x forward P/E. Dive into our free research report to see why there are better opportunities than CVS.
One Stock to Buy:
Nova (NVMI)
Trailing 12-Month GAAP Operating Margin: 29%
Headquartered in Israel, Nova (NASDAQ: NVMI) is a provider of quality control systems used in semiconductor manufacturing.
Why Should You Buy NVMI?
- Impressive 23.4% annual revenue growth over the last five years indicates it’s winning market share this cycle
- Disciplined cost controls and effective management resulted in a strong two-year operating margin of 29%, and its operating leverage amplified its profits over the last five years
- Earnings per share grew by 27.4% annually over the last five years and trumped its peers
Nova is trading at $398.25 per share, or 30.6x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
